Cornercap投资咨询公司购买了Jazz制药公司的重要股份,该公司价值74.7亿美元。 Cornercap Investment Counsel Inc. bought a significant stake in Jazz Pharmaceuticals, a company valued at $7.47 billion.

投资公司Cornercap投资咨询公司购买了价值518 000美元的Jazz制药公司股票,而先锋集团公司略微减少了持有量。 Investment firm Cornercap Investment Counsel Inc. bought $518,000 worth of Jazz Pharmaceuticals stock, while Vanguard Group Inc. slightly decreased its holdings. 分析师对专业制药公司给予“Buy”共识评级,目标价格为187.71美元。 Analysts have a "Buy" consensus rating for the specialty pharmaceutical company, with a target price of $187.71. Jazz制药公司价值74.7亿美元,提供精神病和癫痫综合症的治疗。 Jazz Pharmaceuticals, valued at $7.47 billion, offers treatments for narcolepsy and epilepsy syndromes.